LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription

• Published in: Cell death & disease Vol. 12; no. 2; p. 201
• Main Authors: Xie, Xina, Lin, Jiatian, Fan, Xiaoqin, Zhong, Yuantang, Chen, Yequn, Liu, Kaiqing, Ren, Yonggang, Chen, Xiangling, Lai, Daihuan, Li, Xuyi, Li, Zesong, Tang, Aifa
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.02.2021; Springer Nature B.V; Nature Publishing Group
• Subjects: 13; 13/105; 13/89; 38/39; 38/77; 38/90; 45/15; 631/337/384/2568; 692/699/67/589/1588/1351; 82/1; 82/51; Animals; Antibodies; Biochemistry; Biomedical and Life Sciences; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - metabolism; Carcinoma, Renal Cell - pathology; Cell Biology; Cell Culture; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Cell migration; Cell Movement; Cell Proliferation; Chemotherapy; CREB-binding protein; Cyclic AMP response element-binding protein; Cyclin-dependent kinase; Cyclin-dependent kinases; Databases, Genetic; Disease Progression; DNA Methylation; Enzyme inhibitors; Epigenesis, Genetic; Epigenetics; Gene Expression Regulation, Neoplastic; Humans; Immunology; Insulin; Kidney Neoplasms - genetics; Kidney Neoplasms - metabolism; Kidney Neoplasms - pathology; Kinases; Life Sciences; Male; Malignancy; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Proteins; Radiation therapy; Renal cell carcinoma; RNA Stability; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; RNA-Binding Proteins - genetics; RNA-Binding Proteins - metabolism; Signal Transduction; Transcription; Transcriptional Activation; Tumor Burden
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-021-03489-y

Because of the lack of sensitivity to radiotherapy and chemotherapy, therapeutic options for renal clear cell carcinoma (KIRC) are scarce. Long noncoding RNAs (lncRNAs) play crucial roles in the progression of cancer. However, their functional roles and upstream mechanisms in KIRC remain largely unknown. Exploring the functions of potential essential lncRNAs may lead to the discovery of novel targets for the diagnosis and treatment of KIRC. Here, according to the integrated analysis of RNA sequencing and survival data in TCGA-KIRC datasets, cyclin-dependent kinase inhibitor 2B antisense lncRNA (CDKN2B-AS1) was discovered to be the most upregulated among the 14 lncRNAs that were significantly overexpressed in KIRC and related to shorter survival. Functionally, CDKN2B-AS1 depletion suppressed cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, CDKN2B-AS1 exerted its oncogenic activity by recruiting the CREB-binding protein and SET and MYND domain-containing 3 epigenetic-modifying complex to the promoter region of Ndc80 kinetochore complex component (NUF2), where it epigenetically activated NUF2 transcription by augmenting local H3K27ac and H3K4me3 modifications. Moreover, we also showed that CDKN2B-AS1 interacted with and was stabilized by insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), an oncofetal protein showing increased levels in KIRC. The Kaplan–Meier method and receiver operating curve analysis revealed that patients whose IGF2BP3, CDKN2B-AS1 and NUF2 are all elevated showed the shortest survival time, and the combined panel (containing IGF2BP3, CDKN2B-AS1, and NUF2) possessed the highest accuracy in discriminating high-risk from low-risk KIRC patients. Thus, we conclude that the stabilization of CDKN2B-AS1 by IGF2BP3 drives the malignancy of KIRC through epigenetically activating NUF2 transcription and that the IGF2BP3/CDKN2B-AS1/NUF2 axis may be an ideal prognostic and diagnostic biomarker and therapeutic target for KIRC.